Kostal Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 11-12-2024
- Paid Up Capital ₹ 1.41 Cr
as on 11-12-2024
- Company Age 21 Year, 9 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.80 Cr
as on 11-12-2024
- Satisfied Charges ₹ 2.80 M
as on 11-12-2024
- Revenue -19.94%
(FY 2023)
- Profit -92.26%
(FY 2023)
- Ebitda -49.18%
(FY 2023)
- Net Worth 1.81%
(FY 2023)
- Total Assets -6.53%
(FY 2023)
About Kostal Pharma Labs
The Corporate was formerly known as Abhaya Medicine Mart Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.41 Cr.
The company currently has active open charges totaling ₹1.80 Cr. The company has closed loans amounting to ₹2.80 M, as per Ministry of Corporate Affairs (MCA) records.
Vishnu Remella, Kasiviswanadha Remella, and Lakshmi Remella serve as directors at the Company.
- CIN/LLPIN
U51397AP2003PTC042217
- Company No.
042217
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Dec 2003
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Godavari, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Kostal Pharma Labs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kasiviswanadha Remella  | Managing Director | 12-Dec-2003 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vishnu Remella | Director | 12-Dec-2003 | Current |
| Lakshmi Remella | Director | 29-Jun-2011 | Current |
Financial Performance of Kostal Pharma Labs.
Kostal Pharma Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.94% decrease. The company also saw a substantial fall in profitability, with a 92.26% decrease in profit. The company's net worth moved up by a moderate rise of 1.81%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kostal Pharma Labs?
In 2023, Kostal Pharma Labs had a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Overseas Bank Creation Date: 27 Apr 2011 | ₹1.80 Cr | Open |
Indian Overseas Bank Creation Date: 01 Nov 2021 | ₹2.80 M | Satisfied |
How Many Employees Work at Kostal Pharma Labs?
Kostal Pharma Labs has a workforce of 12 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kostal Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kostal Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
